利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.021 秒)

    Compositions containing both sedative and non-sedative antihistamines and sleep aids
    3.
    发明授权
    Compositions containing both sedative and non-sedative antihistamines and sleep aids 有权
    含有镇静和非镇静抗组胺药和睡眠辅助剂的组合物

    公开(公告)号：US07585520B2

    公开(公告)日：2009-09-08

    申请号：US10943311

    申请日：2004-09-17

    申请人： Mark Hirsh ,  Jane Hirsh ,  Whe-Yong Lo

    发明人： Mark Hirsh ,  Jane Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K9/24 ,  A61K9/20 ,  A61K9/22 ,  A61K9/28 ,  A61K9/14

    CPC分类号： A61K45/06 ,  A61K9/209 ,  A61K9/5084 ,  A61K31/00 ,  A61K2300/00

    摘要： Compositions containing both a sedative compound and a non-sedative antihistamine are provided. More particularly, compositions for administration at bedtime containing a sedating antihistamine or other sedating compound in immediate release form and a non-sedating antihistamine in delayed-release form are described. Alternatively, a composition, for administrating upon awakening, containing a non-sedating antihistamine in immediate release form, and a sedating antihistamine or other sedative in delayed-release form is described. Methods of inhibiting the release of histamines by administration of the compositions to a mammalian subject are also provided. The dosage forms may comprise other medications, such as leukotriene receptor antagonists, to enhance the suppression of histamine symptoms.

    摘要翻译： 提供了含有镇静化合物和非镇静抗组胺剂的组合物。 更具体地，描述了在睡前给药的组合物，其含有立即释放形式的镇静抗组胺药或其他镇静化合物和延迟释放形式的非镇静抗组胺药。 或者，描述了用于在觉醒时施用含有立即释放形式的非镇静抗组胺剂的组合物，以及缓释形式的镇静抗组胺药或其他镇静剂。 还提供了通过将哺乳动物受试者施用组合物来抑制组胺释放的方法。 剂型可以包含其他药物，例如白三烯受体拮抗剂，以增强组胺症状的抑制。

    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
    5.
    发明授权
    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent 失效

    公开(公告)号：US06645524B2

    公开(公告)日：2003-11-11

    申请号：US09929838

    申请日：2001-08-14

    申请人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K956

    CPC分类号： A61K9/5084 ,  A61K9/2081 ,  A61K9/209

    摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
    6.
    发明授权
    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent 失效

    公开(公告)号：US06500457B1

    公开(公告)日：2002-12-31

    申请号：US09639584

    申请日：2000-08-14

    申请人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K920

    CPC分类号： A61K9/5084 ,  A61K9/2081 ,  A61K9/209

    摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

    Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
    7.
    发明授权
    Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration 失效
    用于口内和口服给药的具有模制的triturate片剂的压缩环形片剂的药物组合物

    公开(公告)号：US07387792B2

    公开(公告)日：2008-06-17

    申请号：US11041474

    申请日：2005-01-24

    申请人： Jane C. Hirsh ,  Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Jane C. Hirsh ,  Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/24 ,  A61K9/46

    CPC分类号： A61K9/209 ,  A61K9/0056

    摘要： New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient, which comprises: (a) as a first portion, at least one discrete molded triturate tablet comprising a therapeutically effective amount of at least one pharmaceutically active ingredient capable of intraoral administration; and (b) as a second portion located around the said first portion, a therapeutically effective amount of at least one pharmaceutically active ingredient capable of oral administration and which is releasable and orally ingestible by the patient after the molded triturate tablet has disintegrated or has dissolved intraorally.

    摘要翻译： 公开了单位剂量形式的新的药物组合物，用于向患者进行口内和口服给药，所述单位剂型被配置为置于所述患者的口内，其包括：（a）作为第一部分，至少一个离散的模制成型的片剂 包括治疗有效量的至少一种能口内给药的药物活性成分; 和（b）作为位于所述第一部分周围的第二部分，治疗有效量的至少一种能够口服给药的药学活性成分，并且其在模制的特定片剂崩解或溶解之后由患者可释放和口服摄入 口语

    Compositions and Methods for the Treatment of Wounds and Scar Tissue
    8.
    发明申请
    Compositions and Methods for the Treatment of Wounds and Scar Tissue 审中-公开
    伤口和疤痕组织治疗的组成和方法

    公开(公告)号：US20080317830A1

    公开(公告)日：2008-12-25

    申请号：US11768053

    申请日：2007-06-25

    申请人： Jay A. Goldstein ,  Bernard Grubstein ,  Michael Rothman ,  Whe-Yong Lo ,  Patrea L. Pabst

    发明人： Jay A. Goldstein ,  Bernard Grubstein ,  Michael Rothman ,  Whe-Yong Lo ,  Patrea L. Pabst

    IPC分类号： A61K33/24 ,  A61K33/08 ,  A61K33/30 ,  A61L15/18 ,  A61K33/12

    CPC分类号： A61K33/08 ,  A61K33/06 ,  A61K33/24 ,  A61K33/30 ,  A61L15/18 ,  A61L26/0004

    摘要： Compositions for the treatment of wounds and/or scars are described herein. The compositions contain between 1 and up to 30% by weight, more preferably between 1 and 20%, most preferably between about 5 and 10% by weight particles, such as titanium dioxide or a similar material in a pharmaceutically acceptable base or carrier, such as petrolatum. The compositions are less greasy than petrolatum alone, and thus are more aesthetically pleasing. The compositions exhibit occlusive properties comparable to petrolatum. The compositions are absorbed into the skin, unlike petrolatum, and exhibit significant wound healing characteristics not observed with petrolatum alone. In one embodiment, the pharmaceutically acceptable base is petrolatum and the particles are titanium dioxide. The compositions can be used to treat complex, hard to heal wounds, such as diabetic ulcers; pressure sores, such as bed sores; lacerations; bite wounds; burns; penetrating wounds; surgical wounds, etc. The composition can also be used to promote normal healing of scar tissue. The compositions can also be used for the topical delivery of one or more active agent. The compositions can be used to reduce fine lines and wrinkles, and to rehydrate skin or to treat dry skin.

    摘要翻译： 本文描述了用于治疗伤口和/或伤痕的组合物。 组合物含有1至高达30重量％，更优选1至20重量％，最优选约5至10重量％的颗粒，例如二氧化钛或药学上可接受的碱或载体中的相似材料，例如 作为凡士林。 组合物比单独的凡士林油脂少，因此更美观。 该组合物表现出与凡士林相当的闭塞性质。 组合物被吸收到皮肤中，与凡士林不同，并且表现出明显的伤口愈合特征，单独用凡士林观察不到。 在一个实施方案中，药学上可接受的碱是凡士林，并且颗粒是二氧化钛。 组合物可用于治疗复杂的难愈合伤口，例如糖尿病性溃疡; 压疮，如褥疮; 撕裂 咬伤 烧伤 穿透伤口; 手术伤口等。组合物也可用于促进瘢痕组织的正常愈合。 组合物也可用于局部递送一种或多种活性剂。 该组合物可用于减少细纹和皱纹，并使皮肤脱水或治疗干性皮肤。

    Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms
    9.
    发明申请
    Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms 审中-公开
    液体剂型中含硫药物的药物制剂

    公开(公告)号：US20070134277A1

    公开(公告)日：2007-06-14

    申请号：US11297639

    申请日：2005-12-09

    申请人： Wen Chen ,  Michael Shannon ,  Vimonrat Umprain ,  Whe-Yong Lo ,  Karl Weinrich

    发明人： Wen Chen ,  Michael Shannon ,  Vimonrat Umprain ,  Whe-Yong Lo ,  Karl Weinrich

    IPC分类号： A61K9/00 ,  A61K31/198

    CPC分类号： A61K45/06 ,  A61K31/095 ,  A61K31/195 ,  A61K2300/00

    摘要： The pharmaceutical formulations of the invention for masking the odor from the sulfur-containing active agent comprise at least one sulfur-containing active agent, an effective amount of at least one flavoring agent. Any flavoring agent or combinations of flavoring agents may be used in the pharmaceutical formulation of the invention. The flavoring agent may be natural flavors, natural fruit flavors, artificial flavors, and mixtures thereof. The pharmaceutical formulation may contain an artificial sweetener, a natural sweetener or mixtures thereof. The pharmaceutical formulations are provided in liquid dosage form or a dry powder dosage form for reconstitution in water. Stabilizer added as one of expicients can extend the stability of the pharmaceutical formulation liquid dosage form for a period of at least 30 days when the formulation is stored below room temperature. The pharmaceutical formulations of the invention are palatable and particularly useful for the administration of sulfur-containing drugs to very small children that are in need of such medications. Methods of forming a liquid dosage form of pharmaceutical formulation by adding water to the dry powder form, methods to prepare an odor-masking pharmaceutical formulation and methods for treating lead poisoning or Wilson's disease using the odor-masking pharmaceutical formulation are also provided.

    摘要翻译： 用于掩蔽来自含硫活性剂的气味的本发明的药物制剂包含至少一种含硫活性剂，有效量的至少一种调味剂。 任何调味剂或调味剂的组合可用于本发明的药物制剂中。 调味剂可以是天然香料，天然水果香料，人造香料及其混合物。 药物制剂可以含有人造甜味剂，天然甜味剂或其混合物。 药物制剂以液体剂型或干粉剂型提供，用于在水中重构。 作为顾客之一添加的稳定剂可以将制剂储存在室温以下时将药物制剂液体剂型的稳定性延长至少30天。 本发明的药物制剂是可口的，并且特别可用于向需要这种药物的非常小的儿童施用含硫药物。 还提供了通过向干粉形式中加入水形成药物制剂的液体剂型的方法，制备防气味药物制剂的方法和使用该气味掩蔽药物制剂治疗铅中毒或威尔逊病的方法。

    Antifungal formulations
    10.
    发明授权
    Antifungal formulations 有权
    抗真菌配方

    公开(公告)号：US08232304B2

    公开(公告)日：2012-07-31

    申请号：US10691928

    申请日：2003-10-23

    申请人： Jay A. Goldstein ,  Michael Rothman ,  Whe-Yong Lo

    发明人： Jay A. Goldstein ,  Michael Rothman ,  Whe-Yong Lo

    IPC分类号： A61K31/415 ,  A61K31/58 ,  A61K31/56 ,  A61K9/06 ,  A61K9/08 ,  A61K9/12 ,  A61K9/14

    CPC分类号： A61Q17/005 ,  A61K8/63 ,  A61K9/0014 ,  A61K31/00 ,  A61K31/4174 ,  A61K31/57 ,  A61K45/06 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/44 ,  A61Q19/00 ,  A61K2300/00

    摘要： A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. In a representative example, the low potency anti-inflammatory steroid has the following structure: wherein R1, R2, R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups; R1 and R2 taken together can be C3-C10 cycloalkyl; and R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups. The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. The composition can be used to treat a fungal disease such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, and candidiasis as well as intertriginous dermatitis complicated by candidiasis.

    摘要翻译： 一种外用组合物和使用该组合物的方法，其含有抗真菌剂和安全有效的低效抗炎类固醇，例如去氧化物或其衍生物。 低效甾类药物不会引起副作用，如皮肤萎缩，皮肤色素沉着和色素沉着不足。 在代表性的例子中，低效抗炎类固醇具有以下结构：其中独立地取代的R 1，R 2，R 3和R 4可以是H，C 1 -C 10烷基，C 1 -C 10烯基，C 3 -C 10环烷基和苯基 ; R 1和R 2一起可以是C 3 -C 10环烷基; R 3和R 4独立地可以是H，C 1 -C 10烷基，C 1 -C 10烯基，C 3 -C 10环烷基，苯基，C 7 -C 10苯基烷基，羧酸酯，磺酰基，磷酰基和膦酰基。 组合物可以配制成剂型，例如霜剂，软膏剂，凝胶剂，洗剂，泡沫剂，粉剂，气雾剂，喷雾剂，洗发剂或液体溶液。 该组合物可用于治疗真菌性疾病，例如足癣，头癣，体癣，花斑斑，斑癣和念珠菌病以及由念珠菌病复杂的间质性皮炎。